Results 31 to 40 of about 180,170 (299)

The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment

Frontiers in Oncology, 2021
Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells (PCs) that develop at multiple sites within the bone marrow (BM). MM is treatable but rarely curable because of the frequent emergence of drug resistance and relapse.
Jihane Khalife, Jihane Khalife, James F. Sanchez, Flavia Pichiorri, Flavia Pichiorri   +4 more
doaj   +1 more source

Direct-to-patient research: Opportunity brings challenges

Cancer Treatment and Research Communications
Direct-to-patient (DTP) research offers promising alternatives to traditional models, potentially improving population-level data collection to understand disease initiation, progression, and response to treatment.
Anne Quinn-Young, Michael Andreini, Arianna Haynes, Niccolo Pabustan, Jessica Schulman, Mercedes Martillo, Katie Wozniak, Hearn Jay Cho, George Mulligan   +8 more
doaj   +1 more source

Widespread intronic polyadenylation diversifies immune cell transcriptomes

Nature Communications, 2018
Recognition of intronic polyadenylation (IpA) signals can lead to expression of truncated proteins lacking C terminal domains. Analysis of 3ʹ -seq and RNA-seq shows that IpA is widespread in circulating immune cells, while multiple myeloma cells show ...
Irtisha Singh, Shih-Han Lee, Adam S. Sperling, Mehmet K. Samur, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Christine Mayr, Christina S. Leslie   +8 more
doaj   +1 more source

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury

Blood Advances
: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes.
E. Bridget Kim, Jack E. Malespini, Matthew Lei, Samuel S. Han, Cole W. Minsky, Andrew R. Branagan, Elizabeth K. O’Donnell, Diana Cirstea, Noopur S. Raje, Andrew J. Yee   +9 more
doaj   +1 more source

Orbital Metastasis of Multiple Myeloma: Case Report [PDF]

, 2016
A 68-year-old woman with a history of multiple myeloma presented to the clinic with pain and vision loss in her right eye. Proptosis was observed in her right eye and eye movements were restricted in all directions. Best corrected visual acuity was 3/10
Erdinç Nayir, Mustafa Vatansever, Eda Bengi Yılmaz   +2 more
core   +1 more source

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma [PDF]

, 2023
To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of ...
Raje, Noopur, Munshi, Nikhil, Angela Dispenzieri, Moreau, Philippe, Anderson, Kenneth C., Noopur Raje, Mateos, Maria Victoria, Peter Voorhees, Maria-Victoria Mateos, Dispenzieri, Angela, Aurore Perrot, Brian G. Durie, Thierry Facon, Peter O’Gorman, Kumar, Shaji K., O’Donnell, Elizabeth K., Philippe Moreau, O’Gorman, Peter, Bladé, Joan, Kenneth C. Anderson, Nikhil Munshi, Lonial, Sagar, Voorhees, Peter, Perrot, Aurore, Richardson, Paul G., Laubach, Jacob P., Paul G. Richardson, Rosiñol, Laura, Durie, B., Elizabeth O’Donnell, Sagar Lonial, Facon, Thierry, Shaji Kumar, Joan Bladé, Laura Rosiñol, Jacob P. Laubach   +35 more
core   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

Multiple Myeloma : an update on disease biology and therapy [PDF]

, 2004
Multiple myeloma is a malignancy of immunoglobulin producing plasma cells. Clinical features include bone pain due to lytic bone lesions or pathological fractures, anemia, symptomatic hypercalcemia, renal insufficiency, recurrent infections and ...
Dingli, David, Cook, Rachel J.
core  

Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma

Blood Cancer Journal
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood.
Rie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, Tsuyoshi Fukushima, Ryan S. Han, Rajib Shome, Kiyosumi Ochi, Cristina Panaroni, Keertik Fulzele, Farah Rexha, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, David T. Scadden, Noopur S. Raje   +14 more
doaj   +1 more source